Literature DB >> 24140597

Toxoplasma gondii infection: What is the real situation?

Waenurama Chemoh1, Nongyao Sawangjaroen, Veeranoot Nissapatorn, Chitkasaem Suwanrath, Verapol Chandeying, Thanaporn Hortiwakul, Hemah Andiappan, Natthawan Sermwittayawong, Bunsri Charoenmak, Pisut Siripaitoon, Amorn Lekkla, Yaowalark Sukthana.   

Abstract

The prevalence of chronic Toxoplasma infections reported in the literature varies enormously. We hypothesize that one factor could be due to the different methods used in the evaluation of infections. Serological evidence of Toxoplasma infections in 450 pregnant women (PW) and 300 HIV-infected patients (HIV) were investigated by the Sabin-Feldman dye test and two other commercial ELISA kits (kit1 and kit2). Anti-Toxoplasma IgG antibodies obtained from the Sabin-Feldman dye test, ELISA kit1 and ELISA kit2 in the PW subjects were 14.7%, 29.6% and 38.7%, and in the HIV subjects were 13%, 34.7% and 36.3%, respectively. So there were significant differences in the seroprevalences when different diagnostic tests were used (P<0.05). Regarding Sabin-Feldman dye test as the gold standard for anti-Toxoplasma antibodies detection, we found that the sensitivity and specificity of the ELISA kit1 and kit2 was in the range of their specification. However as the two ELISA kits used in our study identified a much higher prevalence of Toxoplasma infections which indicated that false positive cases were being reported. Based on results obtained, it is therefore highly recommended that research workers should be aware that the reports of serological studies in terms of high positive results should be treated with some skepticism until additional precise diagnostic tools are developed.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ELISA test; Pregnant women and HIV-infected patients; Sabin–Feldman dye test; Seroprevalence; Toxoplasma gondii

Mesh:

Substances:

Year:  2013        PMID: 24140597     DOI: 10.1016/j.exppara.2013.10.001

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  6 in total

1.  Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.

Authors:  Hongfei Si; Chunyan Xu; Jili Zhang; Xukun Zhang; Bing Li; Xuzheng Zhou; Jiyu Zhang
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-03-01       Impact factor: 4.077

2.  Validation of Multiplex Serology for human hepatitis viruses B and C, human T-lymphotropic virus 1 and Toxoplasma gondii.

Authors:  Nicole Brenner; Alexander J Mentzer; Julia Butt; Kathrin L Braband; Angelika Michel; Katie Jeffery; Paul Klenerman; Barbara Gärtner; Paul Schnitzler; Adrian Hill; Graham Taylor; Maria A Demontis; Edward Guy; Stephen J Hadfield; Rachael Almond; Naomi Allen; Michael Pawlita; Tim Waterboer
Journal:  PLoS One       Date:  2019-01-07       Impact factor: 3.240

Review 3.  Seroprevalence of ToRCH Pathogens in Southeast Asia.

Authors:  Franziska E Fuchs; Maude Pauly; Antony P Black; Judith M Hübschen
Journal:  Microorganisms       Date:  2021-03-11

4.  Evaluation of Origanum vulgare Essential Oil and Its Active Ingredients as Potential Drugs for the Treatment of Toxoplasmosis.

Authors:  Na Yao; Qiong Xu; Jia-Kang He; Ming Pan; Zhao-Feng Hou; Dan-Dan Liu; Jian-Ping Tao; Si-Yang Huang
Journal:  Front Cell Infect Microbiol       Date:  2021-11-22       Impact factor: 5.293

5.  Toxoplasma gondii - Prevalence and Risk Factors in HIV-infected Patients from Songklanagarind Hospital, Southern Thailand.

Authors:  Waenurama Chemoh; Nongyao Sawangjaroen; Pisut Siripaitoon; Hemah Andiappan; Thanaporn Hortiwakul; Natthawan Sermwittayawong; Bunsri Charoenmak; Veeranoot Nissapatorn
Journal:  Front Microbiol       Date:  2015-11-25       Impact factor: 5.640

6.  Continuous Decline of Toxoplasma gondii Seroprevalence in Hospital: A 1997-2014 Longitudinal Study in Paris, France.

Authors:  Nicolas Guigue; Lucie Léon; Samia Hamane; Maud Gits-Muselli; Yann Le Strat; Alexandre Alanio; Stéphane Bretagne
Journal:  Front Microbiol       Date:  2018-10-05       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.